tirzepatide gip/glp-1 Tirzepatide's Unique Mechanism of Action Mounjaro Science: How GIP &

Your healthcare provider may review your current medications to identify any interactions or consider alternative treatments if anxiety persists or worsens

Nausea occurs in 25-35% of users during dose escalation phases

They compared tirzepatide to insulin degludec in a specific group of patients participating in the SURPASS-3 study

SAN DIEGO Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions

Many GLP-1 medication users report reduced thirst during treatment, which increases dehydration risk

For obesity treatment, the relevant comparison is Zepbound vs